The article by K . F. Faull and his colleagues entitled "Metabolic Studies on Two Patients with Non-hepatic Tyrosinemia Using Deuterated Tyrosine Loads" (3) raises several points which appear to us to require comment. The term "non-hepatic tyrosinemia" is inappropriate for a disorder in which hepatic enzymes are alleged to be deficient and only serves to complicate the present nomenclature. The tyrosinemia which is associated with liver damage and a Fanconi syndrome is clinically quite distinct from the tyrosinemia associated with eye and skin lesions and mental retardation without liver damage. In order to distinguish these two clinical entities we have called them type 1 and type 2, respectively (2).
The enzyme assays in Dr. Faull's study are critically inadequate. Since liver contains a nonspecific mitochondria1 transaminase (aspartate aminotransferase) capable of accepting tyrosine as substrate (1 1) any meaningful investigation of tyrosine aminotransferase must be carried out on supernatant fractions of liver homogenates (7, 8) . Granner's method requires the use of diethyldithiocarbamate as an inhibitor of hydroxylase activity in fresh liver samples and this was not employed. Moreover, saturating concentrations of substrate were not present in the assay for p-hydroxyphenylpyruvate hydroxylase activity even if all the [14C]tyrosine was converted to ketoacid. Finally, the choice of a paper chromatographic procedure is baffling when more simple, sensitive, and accurate methods already exist (5, l o , 12) .
The rH]tyrosine experiments are predicated on the retention of the 2H on the phenolic ring during its metabolic passage. This must be constant for any meaningful interpretation of these experiments. Under physiologic conditions, 2H exchange at the ortho position of tyrosine could be considerably greater than under the strong acid conditions employed by the authors to establish stability of the labeling. We thus have no means of interpreting the reported urinary metabolic results which might vary with storage and even with the pH of the urine. Indeed, the 'H study may be more misleading than instructive. The [2H]tyrosine load (120 mg/kg) could not dissolve in 100 ml as described by the authors; moreover, at the pH of ileal fluid, the solubility is only about 750 mg/liter. The stool content of 2 H compounds is not mentioned and failure of absorption could account for a substantial proportion of the load. Some evidence for this is apparent from the 165-fold increase in urinary phydroxyphenylacetate after 2H-tyrosine load in their normal subject. It has been established that the bulk, if not all, of the urinary p-hydroxyphenylacetate originates from gut bacterial action on tyrosine (1, 6) . Furthermore, the blood levels of ['Hltyrosine in patients continued to increase for 8 hrs, which also suggests delayed absorption of the amino acid from the gut.
The statement that the "pattern of urinary metabolites indicated a persistent defect in p-hydroxyphenylpyruvic acid oxidase" is simplistic. It certainly appears that both Faull's patients handled the 12Hltyrosine load very differently but to use this . -. data to postulate substrate inhibition of p-hydroxyphenylpyruvate hydroxylase in vivo is fallacious. The so-called substrate inhibition is-a contrivance of the enzyme assay in which oxygen inactivation of the enzyme occurs in the presence of the ketoacid. At physiologic PO, no inhibition is observed (5). The urinary metabolite patterns and the different handling of a tyrosine load in the two patients could just as well be explained by a difference in the amount of residual cytosol tyrosine aminotransferase activity. In this condition, the ketoacid accumulates as a result of mitochondrial transamination of tyrosine in tissues which lack the hydroxylase (4, 9) .
In summary, it is regrettable that a decisive investigation of the enzyme defects was not achieved. It is clear that these patients did not have tyrosinemia type 1 but it remains uncertain as to whether they both had tyrosinemia type 2 o r whether one had a primary defect in p-hydroxyphenylpyruvate hydroxylase.
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Thank you for the opportunity of replying to the criticisms of Dr. Buist and colleagues. The terminology of tyrosinemia is indeed confusing. Perhaps we should have used the term "tyrosinemia without liver damage."
We recognize deficiencies in the enzyme assays and therefore laid rather little weight upon these results in our argument; however, there were clear differences between the two patients. We can firmly dismiss the suggestion that deuterium atoms have been lost from the phenolic ring by chemical exchange during storage because such a process would alter the ratio of the D, to the D, peaks on mass spectrometry, producing an increase in the D, peak and a decrease in the D, peak. The ratio of these peaks was monitored in all samples and did not change significantly.
Absorption of the tyrosine loads used was clearly slow and probably incomplete. Parenteral administration of a smaller load would undoubtedly be preferable. Nonetheless, as our critics themselves point out, the studies of the control subject give us some idea of the amount of phenolic acids contributed by absorption of the products of bacterial metabolism and this is clearly far too small to have any influence on the overall results obtained.
We are left with the principal observation of our study basically unaltered by the criticisms raised. One patient excreted approximately the same very large proportion of the administered label in the urine whether he was tested with high serum tyrosine o r with serum tyrosine reduced by dietary treatment. In the other patient the dietary control resulted in a 100-fold reduction of the proportion of the label excreted in the urine as tyrosine and tyrosyl derivatives.
In considering these results it is important to note that the serum tyrosine level was still 2-3 times the upper limit of normal in both patients while on dietary treatment and so the rate-limiting step of tyrosine catabolism was already overloaded before the labeled tyrosine load was administered. Consequently, one should expect the handling of the load to be comparable in the two patients under these circumstances if indeed the two patients had defects of the same enzyme as
